China-Europe Pharma Dealmaking in 2027: Trends and Opportunities

Join SS&C Intralinks and a panel of industry experts on Tuesday 1 December 2026 as we examine the outlook for China-Europe pharmaceutical licensing, partnering, and M&A activity in 2027. Featuring seasoned dealmakers and life sciences leaders from across China and Europe, this discussion will explore emerging opportunities, evolving buyer and investor priorities, and the key factors expected to influence cross-border transaction activity in the year ahead.

This webinar will explore:

• Key trends expected to shape China-Europe licensing, partnering, and M&A activity in 2027
• How European pharmaceutical companies and investors are evaluating China-originated assets
• The growing importance of data readiness and due diligence preparation in successful deal execution
• Regulatory, compliance, and cross-border data considerations that can impact transaction timelines
• Practical strategies to improve deal readiness and maximize transaction value

Session length: 45mins